ES2287940T3 - Composiciones estables que contienen n-propargil-1-aminoindano. - Google Patents

Composiciones estables que contienen n-propargil-1-aminoindano. Download PDF

Info

Publication number: ES2287940T3
Authority: ES; Spain
Prior art keywords: pharmaceutical composition; propargil; aminoindane; weight; pharmaceutically acceptable
Prior art date: 1995-09-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

ES96930344T

Other languages

English (en)

Spanish (es)

Inventor

Tirtsah Berger Peskin

Fanny Caciularu

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Teva Pharmaceutical Industries Ltd

Original Assignee

Teva Pharmaceutical Industries Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-09-20

Filing date

1996-09-18

Publication date

2007-12-16

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11068003&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2287940(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-09-18 Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd

2007-12-16 Application granted granted Critical

2007-12-16 Publication of ES2287940T3 publication Critical patent/ES2287940T3/es

2016-09-18 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title claims abstract description 34
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 32
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 24
150000003839 salts Chemical class 0.000 claims abstract description 10
239000004480 active ingredient Substances 0.000 claims abstract description 8
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 6
235000019359 magnesium stearate Nutrition 0.000 claims description 5
150000001298 alcohols Chemical class 0.000 claims description 4
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
239000000600 sorbitol Substances 0.000 claims description 2
235000010356 sorbitol Nutrition 0.000 claims description 2
239000000811 xylitol Substances 0.000 claims description 2
235000010447 xylitol Nutrition 0.000 claims description 2
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
229960002675 xylitol Drugs 0.000 claims description 2
229930195725 Mannitol Natural products 0.000 claims 5
239000000594 mannitol Substances 0.000 claims 5
235000010355 mannitol Nutrition 0.000 claims 5
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical group CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract 1
229910052749 magnesium Inorganic materials 0.000 abstract 1
239000011777 magnesium Substances 0.000 abstract 1
238000009472 formulation Methods 0.000 description 15
102000010909 Monoamine Oxidase Human genes 0.000 description 5
108010062431 Monoamine oxidase Proteins 0.000 description 5
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
238000000034 method Methods 0.000 description 3
239000002253 acid Substances 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
239000000945 filler Substances 0.000 description 2
238000005469 granulation Methods 0.000 description 2
230000003179 granulation Effects 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 1
241000207199 Citrus Species 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
239000011149 active material Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
235000020971 citrus fruits Nutrition 0.000 description 1
239000003086 colorant Substances 0.000 description 1
150000001924 cycloalkanes Chemical class 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
-1 glidants Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
IBIKHMZPHNKTHM-RDTXWAMCSA-N merck compound 25 Chemical compound C1C[C@@H](C(O)=O)[C@H](O)CN1C(C1=C(F)C=CC=C11)=NN1C(=O)C1=C(Cl)C=CC=C1C1CC1 IBIKHMZPHNKTHM-RDTXWAMCSA-N 0.000 description 1
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Solid Fuels And Fuel-Associated Substances (AREA)

ES96930344T 1995-09-20 1996-09-18 Composiciones estables que contienen n-propargil-1-aminoindano. Expired - Lifetime ES2287940T3 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IL115357		1995-09-20
IL11535795A IL115357A (en)	1995-09-20	1995-09-20	Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols

Publications (1)

Publication Number	Publication Date
ES2287940T3 true ES2287940T3 (es)	2007-12-16

Family

ID=11068003

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES96930344T Expired - Lifetime ES2287940T3 (es)	1995-09-20	1996-09-18	Composiciones estables que contienen n-propargil-1-aminoindano.

Country Status (13)

Country	Link
US (1)	US6126968A (2)
EP (1)	EP0858328B1 (2)
JP (1)	JP4108750B2 (2)
AT (1)	ATE362755T1 (2)
AU (1)	AU728524B2 (2)
CA (1)	CA2232310C (2)
DE (1)	DE69637096T2 (2)
DK (1)	DK0858328T3 (2)
ES (1)	ES2287940T3 (2)
HU (1)	HU225859B1 (2)
IL (1)	IL115357A (2)
PT (1)	PT858328E (2)
WO (1)	WO1997012583A2 (2)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5744500A (en) *	1990-01-03	1998-04-28	Teva Pharmaceutical Industries, Ltd.	Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL118836A (en)	1996-07-11	2001-01-11	Teva Pharma	Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
IL149308A0 (en)	1999-10-27	2002-11-10	Teva Pharma	Use of 1-aminoindan derivatives for treatment of manic disorders
EP1567152B1 (en)	2002-11-15	2013-08-14	Teva Pharmaceutical Industries Limited	Use of rasagiline with riluzole to treat amyotrophic lateral sclerosis
GB2411355B (en)	2004-02-27	2006-02-22	Niche Generics Ltd	Pharmaceutical composition
EP1778196A4 (en) *	2004-07-26	2008-12-17	Teva Pharma	PHARMACEUTICAL DOSAGES CONTAINING RASAGILINE
WO2006052254A2 (en) *	2004-11-10	2006-05-18	Teva Pharmaceutical Industries Ltd.	Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
US8367105B2 (en)	2004-11-10	2013-02-05	Teva Pharmaceutical Industries, Ltd.	Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
EP1827409B1 (en) *	2004-11-24	2011-08-24	Teva Pharmaceutical Industries, Ltd.	Rasagiline orally disintegrating compositions
HRP20130622T1 (en) *	2005-02-17	2013-08-31	Teva Pharmaceutical Industries Ltd.	Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
US20100167983A1 (en) *	2007-10-22	2010-07-01	Teva Pharmaceutical Industries, Ltd.	Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
CA2901244A1 (en) *	2005-02-23	2006-08-31	Teva Pharmaceutical Industries, Ltd.	Rasagiline formulations of improved content uniformity
JP2009521402A (ja)	2005-11-17	2009-06-04	テバファーマシューティカルインダストリーズリミティド	プロパルギル化アミノインダンの分離のための方法
US7572834B1 (en)	2005-12-06	2009-08-11	Teva Pharmaceutical Industries, Ltd.	Rasagiline formulations and processes for their preparation
CN103142570A (zh)	2005-12-09	2013-06-12	耶路撒冷希伯来大学伊森姆研究发展公司	低剂量Ladostigil 用于神经保护的用途
EP1991214B1 (en)	2006-02-21	2015-08-05	Teva Pharmaceutical Industries, Ltd.	Use of rasagiline for the treatment of multiple system atrophy
TW200744576A (en)	2006-02-24	2007-12-16	Teva Pharma	Propargylated aminoindans, processes for preparation, and uses thereof
EP2007369A4 (en) *	2006-04-03	2009-07-01	Teva Pharma	USE OF RASAGILINE FOR THE TREATMENT OF LEG SYNDROME WITHOUT REST
DE202006020710U1 (de)	2006-05-09	2009-12-31	Teva Pharmaceutical Industries Ltd.	Zusammensetzungen mit Rosiglitazonmaleat
EP1892233A1 (de) *	2006-08-18	2008-02-27	Ratiopharm GmbH	Neue Salze des Wirkstoffs Rasagilin
RS52183B (sr) *	2006-12-14	2012-10-31	Teva Pharmaceutical Industries, Ltd.	Kristalna čvrsta baza razagilina
BRPI0718339A2 (pt)	2006-12-14	2014-02-18	Teva Pharma	Composto, composição, composição farmacêutica e processo de fabricação de tanato de rasagilina
EP1987816A1 (de) *	2007-04-30	2008-11-05	Ratiopharm GmbH	Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
WO2009032273A1 (en) *	2007-09-05	2009-03-12	Teva Pharmaceutical Industries, Ltd.	Method of treating glaucoma using rasagiline
US8188149B2 (en) *	2007-09-17	2012-05-29	Teva Pharmaceutical Industries, Ltd.	Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
WO2009089049A1 (en) *	2008-01-11	2009-07-16	Teva Pharmaceutical Industries, Ltd.	Rasagiline formulations, their preparation and use
US20090247537A1 (en) *	2008-03-25	2009-10-01	William Dale Overfield	Methods for preventing or treating bruxism using dopaminergic agents
WO2009122301A2 (en) *	2008-03-31	2009-10-08	Actavis Group Ptc Ehf	Rasagiline mesylate particles and process for the preparation thereof
BRPI0909894A2 (pt) *	2008-06-13	2015-07-28	Teva Pharma	"método de redução da velocidade de progressão de mal de parkinson em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão de mal de parkinson, método de atraso da necessidade de terapia antiparkinsoniana sintomática em um paciente de mal de parkinson em estágio inicial, método de redução do risco de um paciente com mal de parkinson que necessita de terapia antiparkinsoniana, método de redução do declínio funcional de um paciente com mal de parkinson em estágio inicial, método de redução do declínio funcional em um paciente com mal de parkinson, método de tratamento de um paciente que exibe sinais iniciais de mal de parkinson, método de redução da fadiga em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão clínica e tratamento de sintomas de mal de parkinson em um paciente com mal de parkinson, rasagilina ou um sal farmaceuticamente aceitável de rasagilina, composição farmacêutica.
BRPI0909997A2 (pt)	2008-06-19	2015-10-27	Teva Pharma	r(+)-n-propargil-1-aminoindano cristalino, composição farmacêutica, processo de secagem de r(+)-n-propargil-1-aminoindano sólido, processo de preparação de uma composição farmacêutica, processo de produção de um lote validado de um produto de farmaco que contém r(+)-n-propargil-1-aminoindano cristalino e pelo menos um veículo farmaceuticamente aceitável para distribuição e processo de prudução de r(+)-n-propargil-1-aminoindano cristalino
CA2727021A1 (en) *	2008-06-19	2009-12-23	Teva Pharmaceutical Industries Ltd.	Process for purifying rasagiline base
US20100189791A1 (en) *	2009-01-23	2010-07-29	Teva Pharmaceutical Industries, Ltd.	Delayed release rasagiline malate formulation
EP2218444A3 (en)	2009-01-23	2010-08-25	Teva Pharmaceutical Industries, Ltd.	Delayed release rasagiline formulation
CN102341104A (zh)	2009-03-05	2012-02-01	桑多斯股份公司	含有甲磺酸雷沙吉兰的药物组合物
DK2451771T3 (da)	2009-07-09	2014-09-08	Ratiopharm Gmbh	Salte af rasagilin og farmaceutiske fremstillingsmåder heraf
CN102048717B (zh) *	2009-10-29	2014-02-19	重庆医药工业研究院有限责任公司	一种稳定的雷沙吉兰组合物
EP2515891A4 (en)	2009-12-22	2013-06-05	Teva Pharma	3-keto-N-propargyl-1-aminoindan
JP5820469B2 (ja)	2010-04-30	2015-11-24	テイコクファーマユーエスエーインコーポレーテッド	プロピニルアミノインダンの経皮組成物
EP2389927A1 (en)	2010-05-30	2011-11-30	Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi	Pharmaceutical formulations of rasagiline
WO2012015946A1 (en)	2010-07-27	2012-02-02	Teva Pharmaceutical Industries Ltd.	Dispersion of rasagiline citrate
RU2587330C2 (ru)	2010-07-27	2016-06-20	Тева Фармасьютикал Индастриз Лтд.	Применение разагилина для лечения обонятельной дисфункции
CN103476404B (zh)	2011-03-24	2017-09-29	帝国制药美国公司	包含活性剂层和活性剂转化层的透皮组合物
JP2014534195A (ja) *	2011-10-10	2014-12-18	テバファーマシューティカルインダストリーズリミティド	ラサギリンシトルアミド
HK1200314A1 (en)	2011-10-10	2015-08-07	Teva Pharmaceuticals Usa, Inc.	R(+)-n-methyl-propargyl-aminoindan
HK1200315A1 (en) *	2011-10-10	2015-08-07	Teva Pharmaceutical Industries Ltd.	R(+)-n-formyl-propargyl-aminoindan
WO2013070526A1 (en)	2011-11-09	2013-05-16	Teikoku Pharma Usa, Inc.	Methods for the treatment of skin neoplasms
DE102012000786A1 (de)	2012-01-18	2013-07-18	Stada Arzneimittel Ag	Verfahren zur Herstellung einer festen pharmazeutischen Zusammensetzung, enthaltend den Wirkstoff Rasagilin
EP2827848B1 (en)	2012-03-21	2016-04-27	Synthon BV	Stabilized pharmaceutical compositions comprising rasagiline salts
WO2013175493A1 (en)	2012-04-09	2013-11-28	Cadila Healthcare Limited	Stable oral pharmaceutical compositions
US9308182B2 (en)	2012-08-17	2016-04-12	Teva Pharmaceutical Industries, Ltd.	Parenteral formulations of rasagiline
AU2013338243B2 (en)	2012-11-02	2016-09-29	Teikoku Seiyaku Co., Ltd.	Propynylaminoindan transdermal compositions
EP2796130A3 (en) *	2013-02-06	2015-02-25	Galenicum Health S.L.	Immediate release tablets of rasagiline hemitartrate
ES2502140T1 (es) *	2013-02-06	2014-10-02	Galenicum Health S.L.	Comprimidos de liberación inmediata de rasagilina hemitartrato
CN115400090A (zh) *	2022-10-09	2022-11-29	北京新领先医药科技发展有限公司	一种雷沙吉兰的口崩片组合物及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1187017A (en) *	1966-07-16	1970-04-08	Aspro Nicholas Ltd	Substituted 1-Amino Indanes and Tetrahydronaphthalens
GB8909793D0 (en) *	1989-04-28	1989-06-14	Beecham Group Plc	Pharmaceutical formulation
IL92952A (en) *	1990-01-03	1994-06-24	Teva Pharma	R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
CA2039742A1 (en) *	1990-04-23	1991-10-24	Andrew B. Dennis	Tablet composition and method for problem pharmaceutical materials
IL99759A (en) *	1991-10-16	1997-06-10	Teva Pharma	Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
IL111240A (en) *	1993-10-18	2001-10-31	Teva Pharma	Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
IL112779A (en) *	1994-03-01	1999-11-30	Gergely Gerhard	Granular product or tablet containing an efferescent system and an active pharmaceutical substance and its preparation
PL183266B1 (pl) *	1995-03-02	2002-06-28	Scherer Ltd R P	Doustna kompozycja farmaceutyczna,sposób wytwarzania doustnej kompozycji farmaceutycznej oraz zastosowanie doustnej kompozycji farmaceutycznej

1995
- 1995-09-20 IL IL11535795A patent/IL115357A/xx not_active IP Right Cessation
1996
- 1996-09-18 PT PT96930344T patent/PT858328E/pt unknown
- 1996-09-18 AU AU69427/96A patent/AU728524B2/en not_active Expired
- 1996-09-18 EP EP96930344A patent/EP0858328B1/en not_active Expired - Lifetime
- 1996-09-18 WO PCT/IL1996/000115 patent/WO1997012583A2/en not_active Ceased
- 1996-09-18 DE DE69637096T patent/DE69637096T2/de not_active Expired - Lifetime
- 1996-09-18 US US09/043,475 patent/US6126968A/en not_active Expired - Lifetime
- 1996-09-18 CA CA002232310A patent/CA2232310C/en not_active Expired - Lifetime
- 1996-09-18 DK DK96930344T patent/DK0858328T3/da active
- 1996-09-18 HU HU9802999A patent/HU225859B1/hu unknown
- 1996-09-18 JP JP51411997A patent/JP4108750B2/ja not_active Expired - Lifetime
- 1996-09-18 ES ES96930344T patent/ES2287940T3/es not_active Expired - Lifetime
- 1996-09-18 AT AT96930344T patent/ATE362755T1/de active

Also Published As

Publication number	Publication date
EP0858328A2 (en)	1998-08-19
JP4108750B2 (ja)	2008-06-25
US6126968A (en)	2000-10-03
HUP9802999A3 (en)	1999-05-28
EP0858328A4 (en)	2001-07-11
PT858328E (pt)	2007-08-20
AU728524B2 (en)	2001-01-11
IL115357A0 (en)	1995-12-31
DE69637096T2 (de)	2008-01-31
IL115357A (en)	2000-01-31
JPH11512736A (ja)	1999-11-02
DK0858328T3 (da)	2007-09-03
EP0858328B1 (en)	2007-05-23
WO1997012583A3 (en)	1997-06-05
HUP9802999A2 (hu)	1999-04-28
DE69637096D1 (de)	2007-07-05
HU225859B1 (en)	2007-11-28
AU6942796A (en)	1997-04-28
CA2232310A1 (en)	1997-04-10
ATE362755T1 (de)	2007-06-15
CA2232310C (en)	2008-01-08
WO1997012583A2 (en)	1997-04-10

Publication	Publication Date	Title
US6126968A (en)	2000-10-03	Stable compositions containing N-propargyl-1-aminoindan
US5731000A (en)	1998-03-24	Stabilized pharmaceutical composition containing bupropion
US6281246B2 (en)	2001-08-28	Pharmaceutical composition with sotalol combination and their use in treatment of cardiac ailments
US5114948A (en)	1992-05-19	Stabilized pergolide compositions
KR100227156B1 (ko)	1999-10-15	저장 안정성이 개선된 약학조성물 및 그의 제조방법
JP2752792B2 (ja)	1998-05-18	セレジリンを含有する新規組成物
CA2345622A1 (en)	2000-04-13	Tricyclic .delta.3-piperidines as .alpha.2-antagonists
JPH1192369A (ja)	1999-04-06	医薬品調製物、その製造方法及びシランセトロンの安定化のための酸性添加剤の使用
US20030114391A1 (en)	2003-06-19	Carbinoxamine tannate
JP3995414B2 (ja)	2007-10-24	安定な医薬組成物
ES2256721T3 (es)	2006-07-16	Formulacion de fosinopril.
DE4317646A1 (de)	1994-12-01	Tabletten mit Thioctsäure und mindestens einer basischen Komponente
WO2021216450A8 (en)	2022-06-09	Opioid antagonist formulations
HU225779B1 (en)	2007-08-28	Pharmaceutical composition containing paracetamol and drotaverine and process for producing it
AU771490B2 (en)	2004-03-25	Stable compositions containing N-propargyl-1-aminoidan
US4061747A (en)	1977-12-06	Antidepressant composition
US3993776A (en)	1976-11-23	Anorexigenic process and composition
DE3005029C2 (de)	1987-02-12	Antihypertensive pharmazeutische Zubereitungen
US4470993A (en)	1984-09-11	Therapeutical use of known 5-aminomethyl oxazolidine-2-one derivatives
DE69107207T2 (de)	1995-06-29	Disulfidderivate von mercapto-acyl-aminsäuren.
RU2003125096A (ru)	2005-02-10	Психостимулирующее средство
CA2442898A1 (en)	2005-03-26	Fosinopril sodium tablet formulation
HUP0104359A2 (hu)	2003-06-28	Nicorandilt tartalmazó stabilizált gyógyászati készítmény